Vertex Pharmaceuticals Incorporated (VRTX)

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

As of November 3, 2026, Vertex Pharmaceuticals Incorporated (VRTX) stock slipped to $542.33, down 1.96% (-$10.83) versus the previous close. On the day, shares have traded between $534.75 and $561.96. That puts VRTX in the upper third of its 52-week range of $403.16 to $568.67. Vertex Pharmaceuticals Incorporated operates in the pharmaceutical preparations space and carries a market capitalization of roughly $141.65 billion, with about 402.8K shares changing hands.

Latest VRTX news

• Vertex: 3 Key Takeaways for Long-Term Investorsfool.com· Nov 3, 7:19 AM ET
• Should Strong Q3 Revenue Require Action From Vertex Pharmaceuticals (VRTX) Investors?Yahoo Finance· Nov 3, 6:07 AM ET
• Vertex (VRTX) Q3 2026 Earnings Call Transcriptfool.com· Nov 3, 1:43 AM ET
• Vertex: Q3 Earnings SnapshotYahoo Finance· Nov 2, 11:37 PM ETAP
• Dow Jones Futures: AI Trade Dives As Marvell, Lumentum Plunge; Apple Tumbles On Earnings With Midterm Elections NextYahoo Finance· Nov 2, 9:32 PM ET
• Vertex Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com· Nov 2, 9:14 PM ET
• Krystal Biotech Sinks 11% Despite Q3 Beat as Eye Trial Enrollment “Progressed Slower Than Initially Anticipated”tikr.com· Nov 2, 7:51 PM ET
• Vertex Yo-Yos On Mixed Third-Quarter Report, Light Guidance HikeYahoo Finance· Nov 2, 5:14 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want VRTX headlines, alerts and AI research in one place? Create a free account →

• $VRTX traded about 2.4x its usual volume off the exchanges. Price didn't move much, which is what you'd expect if somebody big is building or unwinding a position quietly. The options side leaned puts the same day. The full dark-pool read, with the options side: https:…

  @GlobalTradersAcademy· Nov 3, 12:58 AM ET

• $VRTX reported after the close on Monday, November 2, 2026: revenue of $3.44B, up 12%, and adjusted EPS (profit per share excluding some items) of $4.76 against about $4.36 expected. It raised its full-year revenue outlook to $13.15B-$13.25B. The stock rose about 3% after hour…

  @Techdamentals· Nov 2, 10:20 PM ET

• Vertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, slightly above the $3.41 billion analyst consensus, while adjusted EPS of $4.76 matched expectations. The company raised its full-year revenue guidance to $13.15–$13.25 billion from $13.10–$13.20 billion, althou…

  @topstockalerts· Nov 2, 8:59 PM ET

• $VRTX - Vertex Pharmaceuticals Q3 Income Statement Explore full income flow chart on https://TenetResearch.ai

  @ripster47· Nov 2, 6:31 PM ET

• https://www.marketbeat.com/earnings/reports/2026-11-2-vertex-pharmaceuticals-incorporated-stock/ $VRTX Vertex Pharmaceuticals Earnings Tra

  @EarningsInsider· Nov 2, 5:46 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →